Introduction
Vinpocetine is a compound that is made in a lab. It mimics a compound found in the periwinkle plant. Vinpocetine has been used to treat symptoms of stroke and brain disorders by helping improve blood flow to the brain. It can be taken as a pill. It can also be injected into the bloodstream by a healthcare provider.
Dosages
10 to 20 milligrams 3 times daily
What Research Shows
Not Enough Data to Assess
Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.
Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.
Safety Notes
It is likely safe to take vinpocetine in small doses for a short time. Not enough studies have been done to say whether it is safe to use for a long period.
Interactions
Talk to your doctor about any supplements or therapy you would like to use. Some can interfere with treatment or make conditions worse.
References
REFA Dementia
REFA1 Balestreri R, Fontana L, et al. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987 May;35(5):425-430.
REFA2 Hindmarch I, Fuchs HH, et al. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991 Spring;6(1):31-43.
REFA3 Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1):CD003119.
REFA4 Perng CH, Chang YC, Tzang RF. The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis. Psychopharmacology (Berl). 2018 May;235(5):1571-1580.
REFB Stroke
REFB1 Feigin VL, Doronin BM, et al. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol. 2001 Jan;8(1):81-85.
REFB2 Kemény V, Molnár S, et al. Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. J Clin Pharmacol. 2005 Sep;45(9):1048-54.
REFB3 Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000480.
REFB4 Zhang W, Huang Y, et al. Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. Clin Drug Investig. 2016;36(9):697-704.
REFB5 Belova LA, Mashin VV, et al. [Possibilities of cavinton therapy regimen for infusions and cavinton comforte in acute and early recovery periods after ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(9):51-58.